



Aureus Pharma Releases DDI Predict 2009 Edition

Aureus demonstrates new application for risk assessment of drug-drug interactions involving multiple enzymatic metabolic pathways at North American Regional ISSX Meeting, October 18-22, 2009, Baltimore

Paris, France, September 17, 2009 -- Aureus Pharma, a leading provider of knowledge management solutions to accelerate discovery in the life sciences industry, announces today the release of the 2009 Edition of DDI Predict. This innovative software application adds a number of enhancements to assess the risk of potential drug-drug interactions including those involving multiple enzymatic pathways.

Drug-Drug interactions (DDIs) are a major concern in the pharmaceutical industry today. DDIs have led to several drugs being removed from the market due to adverse effects, making it essential for pharmaceutical researchers to investigate and understand potential drug-drug interactions as early in the drug development process as possible.

DDI Predict 2009 Edition provides an instant graphical report containing all potential drug-drug interactions between a drug candidate and a large panel of marketed or withdrawn drugs.

The predictions are supported by calculation of the change of the AUC ratio based on the plasma concentration of the drug candidate in the presence or absence of enzyme inhibitors. The system uses a large library containing more than 7,000 inhibition and 8,000 PK data points, measured on 1,500 drugs stored in the Aureus ADME database to calculate potential interactions. The Aureus ADME Knowledge database contains a total 25,000 compounds, 3,500 metabolites, 365,000 biological data points, analyzed out from more than 11,000 articles and FDA documents.

The new Edition extends the prediction of drug-drug interaction in cases where multiple metabolic pathways are involved and provides new functionalities including prediction of fraction metabolized (fm) based on scaling factors (RAF, ISEF, Abundance), gut metabolism and others.

Aureus will present and demonstrate DDI Predict 2009 Edition at the 16th North American Regional ISSX Meeting on October 18 - 22, 2009 at the Baltimore Marriott Waterfront Hotel in Baltimore, Maryland.

See www.aureus-pharma.com for more information

About Aureus Pharma

Aureus Pharma, headquartered in Paris, France, creates and maintains scientific knowledge bases combining chemical and biological, in vitro and in vivo data for a large number of compounds, and provides software applications, which enable scientists to understand the responses of biological targets to compounds under evaluation. The Company captures and organizes data from scientific literature (journals, patents and FDA documents) including details of experimental in vitro and in vivo protocols. Aureus's range of products includes the AurSCOPE® databases focused on the main therapeutic targets in human body: Kinases, Ion Channels, GPCRs, Proteases and Nuclear Receptors. All the therapeutic targets are consolidated in a unified knowledge space, AurSCOPE® Global Pharmacology Space (GPS) which offers researchers a comprehensive coverage of most of the "druggable genome". Other databases related to safety, toxicology, and pharmacokinetics (ADME, hERG) have also been developed. The Company's software applications include a web-based query tool, AurQUEST®, a compound profiling visualization interface, AurPROFILER® and a Drug-Drug Interaction predictive application, DDI Predict ®.

For further information on how Aureus-Pharma helps researchers turn data into discovery visit www.aureus-pharma.com

Press and Analysts Contact

Andrew Lloyd & Associates

Neil Hunter / Andrew Lloyd

neil@ala.com / allo@ala.com

Tel +44 1273 675100
